Cell lines

Human cervical cancer HeLa cells

Preparation Method

Baohuoside I was dissolved in dimethyl sulfoxide (DMSO) as a 10 mM stock solution and stored at 4℃.

Reaction Conditions

Invasion assay by polycarbonate membranes with a pore size of 8 μm，25 μM baohuoside I

Applications

Baohuoside I correlates with cervical cancer cell downregulation of CXC chemokine receptor 4. CXCL12 induced the invasion of cervical cancer cells, and baohuoside I effectively abrogated it.

Animal models

Inbred female C57/BL/6J mice

Preparation Method

Baohuoside I is stored in pure ethanol and suspended in 0.9% sterile saline intraperitoneal injection.

Dosage form

Intraperitoneal injection, 20 mg/kg/d

Applications

Mice received Baohuoside I by daily i.p. injection from day 0 to day 4. They were immunized with sheep red blood cells (SRBC) at day 0 and bled at day 5. The results showed significant suppression of anti-SRBC antibody responses at dosage schedules of 18.8 mg/ kg/day and above (P<0.001).

Baohuoside I, a flavonoid isolated from Epimedium koreanum Nakai, acts as an inhibitor of CXCR4, downregulates CXCR4 expression, induces apoptosis and shows anti-tumor activity^[1].

Baohuoside I exhibited strong inhibition against the α-glucosidase while icariin and epimedin A, B and C were weak or inactive. All compounds were inactive against pancreatic α-amylase. The IC₅₀of baohuoside I was 28.9 μmol/L^[2].A549 cells were evidently inhibited by Baohuoside I in a time- and concentration-dependent manner. IC₅₀was approximately 25.1 μM at 24 h, 11.5μM at 48 h and 9.6μM at 72 h, respectively^[3].

Baohuoside I prolonged graft survival on rat. A negative control group showed a mean survival time of 6.5±0.5 days. Monotherapy with a subtherapeutic oral dose of Baohuoside I (8.0 mg/kg/day) or FK506 (1.0 mg/kg/day) significantly prolonged cardiac allograft survival up to 9.0±2.0 days or 16.4±6.3 days, compared with negative controls. Results with combination therapy of these two drugs in the same doses (25.0±2.0 days) indicate that an additive prolongation of graft survival was produced when compared with monotherapy with Baohuoside I or FK506^[4].

References:
[1]. Kim B, et al. Baohuoside I suppresses invasion of cervical and breast cancer cells through the downregulation of CXCR4 chemokine receptor expression. Biochemistry. 2014 Dec 9;53(48):7562-9.
[2]. M.A.T. Phan, J. Wang, J.Y. Tang, et al. Evaluation of α-glucosidase inhibition potential of some flavonoids from Epimedium brevicornum L. WT-Food Science and Technology, 53 (2013), pp. 492-498.
[3]. Song J, et al. Reactive oxygen species-mediated mitochondrial pathway is involved in Baohuoside I-induced apoptosis in human non-small cell lung cancer. Chem Biol Interact. 2012 Jul 30;199(1):9-17.
[4].A. Ma, S. Qi, D. Xu, X. Zhang, P. Daloze, H. Chen . Baohuoside-1, a novel immunosuppressive molecule, inhibits lymphocyte activation in vitro and in vivo. Transplantation, 78 (2004), pp. 831-838.